Article: H.C. Wainwright Keeps Their Buy Rating on Insmed (INSM)

Article - Media

H.C. Wainwright Keeps Their Buy Rating on Insmed (INSM)

Jason Carr

AnalystRatings, 1 May 2020

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Insmed (INSM – Research Report) today and set a price target of $52.00. The company’s shares closed last Thursday at $23.00.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 7.7% and a 46.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.

Read full article.

Comment: This company is at risk of collusion between a placement agent and naked short sellers.